• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Surgical

Fractyl Health touts preliminary data from diabetes reversal study

January 20, 2022 By Sean Whooley

Fractyl-Logo-CMYK-June2021-02

Fractyl Health this week announced encouraging interim feasibility data from its diabetes reversal technology study. Lexington, Massachusetts–based Fractyl’s Revita-T2Di long-term open-label cohort assessed eight patients followed through at least four weeks having been treated. The company’s Revita system resurfaces the upper intestine lining (duodenal mucosa) to treat metabolic disease in patients with insulin-treated type 2 […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured, Surgical Tagged With: Fractyl Health, fractyllaboratories

Innocoll Biotherapeutics initiates Phase 3 trials for collagen drug-device

April 14, 2021 By Sean Whooley

Innocoll

Innocoll Biotherapeutics announced today that it initiated two Phase 3 trials to support a label expansion for its collagen drug-device implant. Athlone, Ireland-based Innocoll’s trials are seeking label expansion for the FDA-approved Xaracoll (bupivacaine hydrochloride) implant, according to a news release. INN-CB-024, a Phase 3, randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Surgical Tagged With: innocoll

How Bionaut Labs aims to tackle brain tumors with microrobots

March 15, 2021 By Brian Buntz

Bionaut Labs

The roboticist Michael Shpigelmacher was one of the founders of PrimeSense, a robotic 3-D vision technology company Apple acquired in 2013. PrimeSense created technology empowering the Microsoft Xbox Kinect and the iPhone’s Face ID feature, allowing users to use facial recognition to unlock their phones.  Now Shpigelmacher has set his sights on drug-delivery with Bionaut […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Neurological, Oncology, Surgical, Technology Tagged With: 510(k), Bionaut Labs, glioma, Michael Shpigelmacher, Microsoft Kinect, neurology, oncology, PrimeSense

AmacaThera raises $10.3M in oversubscribed Series A

February 22, 2021 By Sean Whooley

AmacaThera announced today that it completed an oversubscribed $10.3 million Series A financing round. Lumira Ventures led the Series A funding, with existing investors Viva BioInnovator and Sprout BioVentures contributing as well. New investors BDC Capital Women in Technology Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures and MaRS IAF participated, too, according […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Hydrogels, Pain Management, Pharmaceuticals, Surgical Tagged With: AmacaThera

OncoSec announces positive results in metastatic melanoma case study

December 4, 2020 By Brian Buntz

Oncosec

The International Journal of Surgery Case Reports has published a case study on the use of the humanized antibody Keytruda (pembrolizumab) and tavokinogene telseplasmid (TAVO) from OncoSec (NSDQ:ONCS) for treating metastatic melanoma. The study involved a patient with stage IIB, pT3b melanoma who initially underwent tumor resection but experienced regional recurrence and later disease progression […]

Filed Under: Immunotherapy, Oncology, Surgical Tagged With: electroporation, Keytruda, melanoma, Oncosec, pembrolizumab, TAVO, tavokinogene telseplasmid

J&J’s Ethicon launches Vistaseal fibrin sealant

December 3, 2019 By Sean Whooley

Ethicon

Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon announced today that it launched its Vistaseal fibrin sealant for managing bleeding during surgery. The sealant system is indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard techniques (suture, ligature, cautery) are ineffective or impractical. Vistaseal fibrin sealant consists […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Hematology, Surgical Tagged With: Ethicon, Grifols

J&J’s Ethicon wins clearance for devices to deliver Grifols surgical sealant

June 19, 2019 By Chris Newmarker

Johnson & Johnson Ethicon Grifols

Johnson & Johnson’s Ethicon has won FDA clearance for airless spray devices to deliver Grifols’ fibrin sealant to stop surgical bleeding, the companies announced today. The Vistaseal fibrin sealant will be the first product Grifols (NSDQ:GRFS) is introducing with Johnson & Johnson (NYSE:JNJ) and Ethicon as part of a global partnership. The 510(k) clearance covers three Vistaseal […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance, Surgical Tagged With: Ethicon, Grifols, Johnson & Johnson

Researchers question use of antibiotic shunts in hydrocephalus patients

January 15, 2019 By Sarah Faulkner

Boston Children's Hospital - updated logo

Led by neurosurgeon Dr. Benjamin Warf, a team of researchers from Boston Children’s Hospital published a study this month questioning the benefits of using shunts impregnated with antibiotics to treat hydrocephalus. Hydrocephalus, which affects roughly 400,000 children each year, is characterized by fluid accumulation in the brain. Surgeons use shunts to drain the patient’s excess […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Research & Development, Surgical Tagged With: Boston Children's Hospital

Intersect ENT touts pooled analysis of steroid-releasing sinus implants

November 19, 2018 By Sarah Faulkner

Intersect ENT updated

Intersect ENT (NSDQ:XENT) last week touted the publication of a pooled analysis of the company’s Propel Contour and Propel Mini steroid-eluting sinus implants. The company’s devices are designed to prop open the sinus ostia following endoscopic sinus surgery. As the implant dissolves, medicine is delivered directly to the sinus lining. The analysis, published in the International Forum […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Surgical, Wall Street Beat Tagged With: Intersect ENT Inc.

EyePoint nabs CMS reimbursement for Dexycu cataract surgery drug

September 7, 2018 By Sarah Faulkner

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (NSDQ:EYPT) said this week that the Centers for Medicare and Medicaid Services approved transitional pass-through status and reimbursement of its dexamethasone intraocular suspension, Dexycu. The FDA-approved product is designed to treat inflammation following cataract surgery using a single, intraocular dose of long-acting dexamethasone. “The receipt of pass-through status and the assignment of a […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Surgical, Wall Street Beat Tagged With: eyepointpharmaceuticals

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 7
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS